Quantcast

Latest MedImmune Stories

2011-01-20 07:30:00

GAITHERSBURG, Md., Jan. 20, 2011 /PRNewswire/ -- MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors. The study, published in the February 1 issue of Cancer Research (a journal of the American Association for Cancer Research), suggests that MEDI-573 inhibits multiple biological pathways related to...

2011-01-10 06:00:00

INCLINE VILLAGE, Nev., Jan. 10, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that on January 7, 2011, the United States District Court for the Northern District of California issued summary judgment order deciding certain issues favorably and other issues adversely to PDL in its litigation with MedImmune. PDL disagrees with certain aspects of the court's decisions which are adverse to the Company and is evaluating its legal options, including appeal of...

2011-01-07 09:28:00

GAITHERSBURG, Md., Jan. 7, 2011 /PRNewswire/ -- MedImmune today announced an in-licensing agreement with Amgen for a novel monoclonal antibody targeting the IL-1 pathway. The antibody, AMG 108, a fully human monoclonal antibody to the IL-1 receptor, has been studied in multiple phase 1 and phase 2 clinical trials and will now be explored by MedImmune for its potential against certain inflammatory diseases. Under the terms of the agreement, Amgen grants MedImmune rights to develop AMG...

2010-12-23 07:45:00

Successes Validate UMd.'s Entrepreneurship Ecosystem COLLEGE PARK, Md., Dec. 23, 2010 /PRNewswire-USNewswire/ -- Martek Biosciences, a company that launched leveraging the Maryland Technology Enterprise Institute (Mtech) at the University of Maryland, entered an agreement on December 21 to be acquired by the Dutch company Royal DSM NV for $1.1 billion, the companies jointly announced. (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO) Martek is the second company sold for more...

2010-12-22 16:00:00

WILMINGTON, Del., Dec. 22, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD(TM) (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011. A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food...

2010-12-22 07:55:00

QUEBEC CITY, QC, Dec. 22 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine").  The Company expects to present interim Phase II...

2010-12-16 19:59:00

WILMINGTON, Del., Dec. 16, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for ticagrelor (BRILINTA(TM)). (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO ) In the CRL, the FDA requested additional analyses of the PLATO data. The agency did not request that additional studies, including clinical studies, be conducted as a prerequisite...

9e7228715b16469262c6262bfe67f9bf1
2010-12-15 08:41:55

A three-year study by Yale School of Medicine researchers has found that vaccinating pregnant women against influenza is over 90 percent effective in preventing their infants from being hospitalized with influenza in the first six months of life. Published in the December 15 issue of Clinical Infectious Diseases, the study builds on preliminary data the research team presented last year at the Infectious Disease Society of America in Philadelphia. Influenza is a major cause of serious...

2010-11-22 13:00:00

Health Officials Stress Importance of Getting Vaccinated HARRISBURG, Pa., Nov. 22, 2010 /PRNewswire-USNewswire/ -- The Department of Health today confirmed a 45-year-old man from Lehigh County as Pennsylvania's first reported flu-related death of the 2010-11 flu season. "This individual was confirmed to have 2009 H1N1, which we know is beginning to circulate," said acting Secretary of Health Michael Huff. "This year's seasonal influenza vaccine provides protection against 2009 H1N1, as...

2010-11-17 09:00:00

GAITHERSBURG, Md., Nov. 17, 2010 /PRNewswire/ -- MedImmune announced the winners of its 5th Annual Research Abstract Competition highlighting the work of the next generation of scientific leaders performing research in areas of respiratory, inflammation and autoimmune (RIA) disease. Graduate students and postdoctoral fellows from around the world were invited to submit abstracts on RIA research as part of a competition sponsored by MedImmune, AstraZeneca's global biologics unit. First...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.